PubMed Journals Articles About "Innovator Award Leukemia Immunotherapies" RSS

17:18 EDT 21st September 2018 | BioPortfolio

Innovator Award Leukemia Immunotherapies PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Innovator Award Leukemia Immunotherapies articles that have been published worldwide.

More Information about "Innovator Award Leukemia Immunotherapies" on BioPortfolio

We have published hundreds of Innovator Award Leukemia Immunotherapies news stories on BioPortfolio along with dozens of Innovator Award Leukemia Immunotherapies Clinical Trials and PubMed Articles about Innovator Award Leukemia Immunotherapies for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Innovator Award Leukemia Immunotherapies Companies in our database. You can also find out about relevant Innovator Award Leukemia Immunotherapies Drugs and Medications on this site too.

Showing "Innovator award leukemia immunotherapies" PubMed Articles 1–25 of 1,200+

2018 ISCB Innovator Award recognizes M. Madan Babu.

2017 ASHG Awards and Addresses.

Each year at the annual meeting of the American Society of Human Genetics (ASHG), addresses are given in honor of the society and a number of award winners. A summary of each of these is provided below. On the following pages, we have printed the presidential address and the addresses for the William Allan Award, Curt Stern Award, and Victor A. McKusick Leadership Award. Webcasts of these addresses, as well as those of many other presentations, can be found at

Rust never sleeps: The continuing story of the Iron Bolt.

Since 1981, Gordon Research Conferences have been held on the topic of Oxygen Radicals on a biennial basis, to highlight and discuss the latest cutting edge research in this area. Since the first meeting, one special feature of this conference has been the awarding of the so-called Iron Bolt, an award that started in jest but has gained increasing reputation over the years. Since no written documentation exists for this Iron Bolt award, this perspective serves to overview the history of this unusual award, ...

Evaluation of a mid-career investigator career development award: Assessing the ability of OppNet K18 awardees to obtain NIH follow-on research funding.

The National Institutes of Health (NIH) K18 award mechanism provides funded opportunities for established investigators to gain knowledge in fields outside of their primary disciplines, but outcomes associated with these awards have not been evaluated to date. NIH's Basic Behavioral and Social Sciences Opportunity Network (OppNet) is one of the few initiatives that has used this award mechanism. We explored how the unique features of K18 awards affect the ability of recipients to obtain follow-on NIH resear...

Pediatric Cancer Immunotherapy: Opportunities and Challenges.

Cancer immunotherapies, widely heralded as transformational for many adult cancer patients, are becoming viable options for selected subsets of pediatric cancer patients. Many therapies are currently being investigated, from immunomodulatory agents to adoptive cell therapy, bispecific T-cell engagers, oncolytic virotherapy, and checkpoint inhibition. One of the most exciting immunotherapies recently FDA approved is the use of CD19 chimeric antigen receptor T cells for pre-B-cell acute lymphoblastic leukemia...

Peter J. Dunn Award / International Solvay Chair in Chemistry for Gernot Frenking / Max Born Prize for Angel Rubio / Terrae Rarae Prize for Rhett Kempe / Frontiers in Chemical Energy Science Award for Karsten Reuter / And also in the News.

Acta Award to Regensburg.

While consuming another solemn sandwich lunch in front of your monitor, why not let your thoughts wander off to a daydream wherein you just won $100,000? This dream just became true for researchers in Regensburg!. For the first time, the recipients of the first-ever Acta Physiologica Award have been selected for the Acta Physiologica Award. Getting there, panning out the biggest nugget, was a challenge and a thrill to every selection committee member. We had a short list of 15 articles, which have been high...

Toxicities with targeted therapies after immunotherapy in metastatic melanoma.

Over the last decade, melanoma treatment has taken rapid strides with the advent of immunotherapies and targeted agents. With these new agents, there has been a significant improvement in patient survival. However, these new treatment options may sometimes lead to unanticipated side effects that make these treatments challenging to administer and monitor. In preclinical studies, BRAF and MEK inhibitors have shown to modulate tumor microenvironment and potentiate immunotherapies. Therefore, some patients who...

Effect of Once Weekly Dulaglutide by Baseline Beta-cell Function in People with Type 2 Diabetes in the AWARD Programme.

Glucagon-like peptide-1 receptor agonists lower blood glucose in T2D partially through glucose-dependent stimulation of insulin secretion. The aim of the study was to investigate whether or not beta-cell function (measured by HOMA2-%B) at baseline affects the glycaemic response to dulaglutide. Dulaglutide-treated patients from AWARD-1, AWARD-3 and AWARD-6 clinical studies were categorised based on their homeostatic model assessment of beta-cell function (HOMA2-%B) tertiles. Changes in glycaemic measures in ...

Transformation from promyelocytic leukemia with t (15; 17) ( q22; q21) to acute monocytic leukemia with t (11; 17) (q23; q21) in a case.

To report on a case of therapy-related acute monocytic leukemia(t-AML) with t(11;17) (q23;q21)/MLL-AF17q after successful treatment for acute promyelocytic leukemia(APL) with t(15;17) (q22;q21)/PML-RARα.

A tribute to Dr. Gordon Hisashi Sato (December 24, 1927-March 31, 2017).

Gordon H. Sato, an innovator in mammalian tissue culture and integrated cellular physiology, passed away in 2017. In tribute to Dr. Sato, In Vitro Cellular and Developmental Biology-Animal presents a collection of invited remembrances from six colleagues whose associations with Dr. Sato spanned more than 40 years. Dr. Sato was a past president of the Tissue Culture Association (now the Society for In Vitro Biology), editor-in-chief of In Vitro Cellular and Developmental Biology (1987-1991), and the recipien...

T-Lymphoblastic Leukemia/Lymphoma With Annular Skin Rash and Epidermotropism.

Leukemia cutis is uncommon in patients with acute lymphoblastic leukemia. It typically presents with dermal papules or subcutaneous nodules, with no epidermal or upper papillary dermal involvement on histopathology. We present an unusual clinical presentation of leukemia cutis, with annular plaques and epidermotropism.


I am submitting my introduction of Dr. Kyle Gustafson for the American Society of Parasitologists Ashton Cuckler New Investigator Award I presented at the ASP annual meeting in Cancun Mexico a few months ago.

Widespread use of measurable residual disease in acute myeloid leukemia practice.

Measurable residual disease (MRD) has prognostic importance for patients with acute myeloid leukemia (AML). How leukemia providers incorporate MRD into routine practice remains undefined.

Treating Adult Acute Lymphoblastic Leukemia in Brazil-Increased Early Mortality Using a German Multicenter Acute Lymphoblastic Leukemia-based regimen.

Acute lymphoblastic leukemia (ALL) in adults is an invariably aggressive and rare disease. Its treatment is based on the use of multidrug regimens, which have been improved since the 1970s. Few published data are available on the results of adult ALL treatment in Latin America.

Clinical and pathological features of myeloid leukemia cutis.

Myeloid leukemia cutis is the terminology used for cutaneous manifestations of myeloid leukemia.

Frank Cole Spencer, MD - Surgeon, Innovator & Educator.

Acute Lymphoblastic Leukemia - Diagnostics, Subgroups and Therapies.

The acute lymphoblastic leukemia (ALL) is a heterogenous rare malignant disease of lymphoblastic precursor cells. The peak of incidence lies in childhood (5.3/100 000), but the incidence rises again from the age of 50 onwards, showing a second peak at patients > 80 years old (2.3/100 000). The ALL is an acute life-threatening disease which untreated leads to death within a short time. The therapeutic objective is cure. By the characterization of subgroups, their targeted therapy and therapy optimizati...

Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.

Exposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Nivolumab to control molecular response in chronic myeloid leukemia.

Characterization of chronic myelomonocytic leukemia with TP53 mutations.

Response kinetics and factors predicting survival in core-binding factor leukemia.

Pseudo Chediak-Higashi anomaly in blasts from acute lymphoblastic leukemia.

Acute promyelocytic leukemia in the intensive care unit: A retrospective analysis.

A phase 1 study of chemosensitization with plerixafor plus G-CSF in adults with relapsed acute myeloid leukemia.

Quick Search